Revolutionizing Cancer Detection: SEQLL’s Groundbreaking Single Molecule Liquid Biopsy Method Published in Nature Biotechnology
SeqLL Announces Breakthrough in Early Cancer Detection BILLERICA, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) — SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL) has made a significant stride in the field of cancer detection with the publication of a new study in the esteemed journal Nature Biotechnology. The study showcases the efficacy of SeqLL’s single-molecule…